Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications
Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertensionHYPER-H21-4 will build on successes witnessed in initial human hypertension studiesThe company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid diseaseLexaria is committed to improving lives and…